Using saffron plant cells to create compounds that protect brain health
Official title: Engineering Saffron Plant Cell Culture to Produce Neuroprotective Bioactives
Funded at Ayana Bio LLC · NIH-11066550 · Data updated 2026-11-12
This study is exploring how natural compounds from saffron plants could help create new treatments for brain conditions like Alzheimer's and ADHD, using tiny worms to test their safety and effectiveness, so that patients might have better options for managing their symptoms.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ayana Bio LLC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 5, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $302,392 |
| NIH project number | 5R43AT012848-02 |
| Project ID | NIH-11066550 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from neurocognitive disorders such as Alzheimer's disease, ADHD, or other related conditions.
✕Less likely to help
Patients with conditions unrelated to neurocognitive disorders may not receive any benefit from this research.
What this research studies
This research focuses on harnessing the bioactive compounds found in saffron plants to develop treatments for various neurocognitive disorders, including Alzheimer's disease and ADHD. The approach involves creating a specialized cell line from saffron that can produce these beneficial compounds in a scalable and cost-effective manner. By using a model organism, C. elegans, the research aims to demonstrate the safety and effectiveness of these compounds in protecting brain health. Patients may benefit from new therapeutic options derived from these plant-based bioactives.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve brain health and cognitive function in patients with neurodegenerative diseases.
How similar studies have gone: Previous research has shown promising results in using plant-derived compounds for neuroprotection, indicating potential success for this novel approach.
Where this research is happening
-
Ayana Bio LLC
Boston, United States Active
Researchers
- Principal investigator: Glenn, Weslee Sinclair — Ayana Bio LLC
- Study coordinator: Glenn, Weslee Sinclair
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.